Thank you for offering to do this.
Could you comment on these 2 articles -
1. Do you know what the MCAP of a company like Arbor is after a funding round like this and is there any comparisons to be drawn with PYCs work in the CRSPR field
https://www.fiercebiotech.com/biotech/arbor-biotechnologies-comes-out-stealth-new-crispr-enzyme
2. If I understand correctly the AAV approach being used by Solid could be considered a competitor technology to PYC’s CPP approach to DMD. Given the news below appears to be a significant failure in that approach does PYC think this increases the appetite to partner with PYC on DMD.
https://www.fiercebiotech.com/biote...s-from-partial-hold-to-full-fda-clinical-hold
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.045(3.63%) |
Mkt cap ! $749.4M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.29 | $1.25 | $337.0K | 265.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 58344 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |